Majority of Oncology Clinical Trials in China Failed to Meet Enrolment Targets
The majority of oncology clinical trials in China that had a start date between 1 January 2012 and 31 December 2017 failed to meet the planned enrolment targets, according to GlobalData, a leading data and analytics company.
The company identified and analyzed enrollment efficiencies of 324 clinical trials during the period and found that on average the enrollment efficiency values of clinical trials across all phases, excluding Phases I/II, fell below 100%.
Although Phase II clinical trials recruited fewer subjects on average (93.1 subjects) relative to Phase II/III (343.3 subjects) and Phase III (513.5 subjects), the greatest discrepancies between planned targets and actual numbers of enrolled subjects was observed in this phase, which had average enrolment efficiencies of 87.8%.
Furthermore, Phase I oncology clinical trials typically failed to meet planned enrolment targets despite enrolling an average of 22.3 subjects in these trials. Combined Phase I/II clinical trials, which typically integrate efficacy and safety purposes into dose-finding objectives, enjoyed the highest enrolment efficiencies and exceeded planned enrolment targets with an average enrolment efficiency of 103.5%.
Due to low numbers of clinical trials with enrolment data available, Phase IV clinical trials were not included in these analyses. The top drugs investigated in these clinical trials include atezolizumab with seven clinical trials, Hutchison Medi Pharma’s fruquintinib with seven clinical trials, Hutchison Medi Pharma’s sulfatinib with six clinical trials, ibrutinib with five clinical trials, and olaparib with five clinical trials.
To gain access to our latest press releases: GlobalData Media Centre. Analysts available for comment. Please contact the GlobalData Press Office:
Asia-Pacific: +91 40 6616 6809
EMEA & Americas: +44 (0)207 832 4399
Email: pr@globaldata.com
To gain access to our latest press releases and expert analysis on developments in your industry, please connect with us on: GlobalData.com | Facebook | LinkedIn | Twitter
About GlobalData
4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.
Total Page Views: 1369